Skip to main content
Premium Trial:

Request an Annual Quote

Serologicals, BMS, Odyssey, EMBL, Alnylam, Eurogentec, Molecular Devices


Serologicals Restructures Research Segment, Hopes to Save $3.5M Annually

Serologicals is cutting costs in its research segment by $3 million to $3.5 million a year by restructuring certain functions, the Atlanta, Ga.-based company said last week.

The company will integrate several functions of its Upstate and Chemicon units through the remainder of the year, including business segment management, R&D/business development, marketing, technical support, scientific sourcing, intellectual property/licensing, and finance and accounting.

Serologicals said it expects to incur between $2 million and $3 million in one-time costs related to severance payments, retention payments, and relocation costs that it will record in the third quarter.

It was unclear as of press time whether the restructuring would involve job cuts. Calls from CBA News sister publication GenomeWeb News to Serologicals were not returned by deadline.

Serologicals, which has more than 1,000 employees worldwide, operates three companies: Chemicon International, based in Temecula, Calif.; Upstate Group, based in Charlottesville, Va.; and Celliance, based in Atlanta.

BMS and Odyssey Partner on Cellular Profiling of Compounds

Odyssey Thera said last week that it has signed an agreement with Bristol Myers Squibb to profile selected BMS compounds using Odyssey's cell-based assays in order to further characterize mechanism of action and pathway activity.

Odyssey will be applying its protein-fragmentation complementation assay technology to the project.

Financial terms of the agreement were not disclosed.

EMBL Genome-Wide RNAi Screen for Genes Associated with Mitosis Nears Halfway Mark

The European Molecular Biology Laboratory is approximately halfway through a human genome-wide siRNA screen to identify genes involved in cell division, RNAi News, a CBA News sister publication, reported last week.

The screen, which is expected to be completed by the end of the year, is part of a larger project called MitoCheck that is focused on determining how phosphorylation regulates mitosis in human cells.

MitoCheck was established in 2004 and is a four-year effort being funded by a roughly €8.5 million ($10.3 million) endowment from the European Union. Its members include the Research Institute of Molecular Pathology in Austria; EMBL; Deutsches Krebsforschungszentrum in Germany; Leica Microsystems Heidelberg; the Max Planck Institute of Molecular Cell Biology and Genetics; Gene Bridges, based in Germany ; the European Institute of Oncology in Italy; Centre de Recherches de Biochimie Macromoléculaire in France; Cancer Research UK; the University College London; and the Wellcome Trust Sanger Institute in the UK.

Austin, Texas-based RNAi firm Ambion is supplying the siRNA library for the screen.

Alnylam Grants RNAi IP License to Eurogentec

Alnylam Pharmaceuticals said last week that it has non-exclusively licensed patents in its Kreutzer-Limmer IP portfolio to life science reagent supplier Eurogentec.

The license enables Eurogentec to use the IP for research products and services, Alnylam said. The patent family covers short interfering RNAs and their use to mediate RNAi in mammalian cells.

The agreement brings to 11 the number of companies to which Alnylam has licensed the patent family. Six of these firms are research product suppliers, the company said.

Molecular Devices Schedules Q2 Earnings Release, Conference Call

Molecular Devices last week said that it will announce its second quarter 2005 earnings on Tuesday, July 26, after the close of regular market trading in the US.

Senior management will hold a conference call on the following day, Wednesday, July 27, at 8 AM Pacific time, to discuss operating results and other business matters.

Interested parties can find dial-in information or access a web cast of the call through a link posted on Molecular Devices' website,

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.